Nutriband Inc. (NASDAQ: NTRB) Makes Approx 42% Overnight Move Surpassing Key Moving Averages

*Sponsored by Nutriband Inc. Market Crux Is Excited to Announce Nutriband Inc. (NASDAQ: NTRB) is Topping Our Watchlist This Morning! And Here’s Why… With fewer than 5.1M shares in the float, Nutriband Inc. (NASDAQ: NTRB) has the setup for significant swings when demand shifts. In under 4 months, (NTRB) moved approximately 314%, proving its capacity to capture. The AVERSA™ Fent-a-nyl patch is a groundbreaking technology redefining patient safety, with projected U.S. sales between $80M and $200M annually if approved. Holding patents in 46 countries and collaborating with major retailers like Walmart and Target, Nutriband is positioning itself for success on both an international and local scale. With a market cap under $50M and record-breaking revenue growth in 2024, Nutriband Inc. (NASDAQ: NTRB) appears to be  flying under the radar—until now. Find out why Nutriband Inc. (NASDAQ: NTRB) has claimed the #1 spot on our watchlist for this morning…… January 22, 2025 Dear Reader, An important update just came across my desk and you need to see it. Noble Capital’s Robert LeBoyer just initiated coverage on Nutriband Inc. (NASDAQ: NTRB) with a bullish rating and a $13 target, which suggests over 97% in upside potential from today’s $6.59 open. At the heart of this optimism is Nutriband Inc. (NASDAQ: NTRB)’s Phase 1 clinical trial, expected to demonstrate the effectiveness of its abuse-deterrent technology.  Noble Capital anticipates this success will lead to a new dr-ug application filing in late 2025 and possible approval in 2026. With a clear path ahead, Nutriband Inc. (NASDAQ: NTRB) is earning attention for all the right reasons. Do you have Nutriband Inc. (NASDAQ: NTRB) on your watchlist today? As of this morning, Nutriband Inc. (NASDAQ: NTRB) is triggering 17 Bullish Signals on TradingView’s technical analysis tool using the 1 hour time-frame. Nutriband Inc. (NASDAQ: NTRB) opened at $6.59, reached $7.45, indicating an approximate 42% overnight move from yesterday's $5.21 close. In doing so, (NTRB) surpassed several key moving averages tracked by Barchart, including: 5-Day: 4.95 20-Day: 4.46 50-Day: 4.56 100-Day: 5.17 200-Day: 5.22 Keep reading if you missed my coverage from earlier and you’ll get caught very quickly… How often do you come across a company in the pharmaceutical space that’s not just playing along but rewriting the script?  Nutriband Inc. (NASDAQ: NTRB) isn’t following trends—it’s blazing its own path. While others stick to the same tired formulas, Nutriband Inc. (NASDAQ: NTRB) is leading the charge with advanced transdermal technologies that tackle some of healthcare’s toughest challenges head-on. Yesterday, Nutriband Inc. (NASDAQ: NTRB) reached $4.83, surpassing its 5-day moving average of $4.23, 20-day at $4.28, and 50-day at $4.52. With its 100-day and 200-day moving averages at $5.15 and $5.20, we’re keeping an eye on this one.  And here’s why it just claimed the #1 spot on our watchlist for this morning: Low Float: With fewer than 5.1M shares in the float, this stock has the potential for significant movement if demand starts to shift. Technical Momentum: Currently trending above multiple key moving averages, the technical signals suggest additional momentum potential. High Growth Potential : With a market cap under $50M, Nutriband is in a position to scale faster than its larger competitors. But that’s not all.  Looking ahead, this week’s Annual Meeting on January 23, 2025, is set to make key decisions on leadership, strategy, and future initiatives—paving the way for what could be a transformative year. Let’s not forget the numbers that already speak for themselves: Nutriband Inc. (NASDAQ: NTRB) moved approximately 314% in less than four months last year (from $2.22 on 3/15/2024 to $9.20 on 7/25/2024). Whether it’s innovation, momentum, or future potential, Nutriband Inc. (NASDAQ: NTRB) is a company that deserves a closer look. In a year when many companies struggled to maintain relevance, Nutriband Inc. (NASDAQ: NTRB) doubled down, fortified its position, and delivered results that speak for themselves.  And if you think 2024 was big, wait until you see what 2025 has in store. Trailblazing with AVERSA™ Fent-a-nyl Nutriband Inc. (NASDAQ: NTRB)’s crown jewel, AVERSA™ Fent-a-nyl, has redefined what’s possible in abuse-deterrent therapeutics.  This groundbreaking transdermal patch is designed not just to combat misuse but to revolutionize patient safety across the board.  With support from Kindeva Dr-ug Delivery, Nutriband Inc. (NASDAQ: NTRB) made significant headway in 2024: Completed pivotal validation studies, advancing the product closer to market readiness. Established a clear regulatory path for its New Application (NDA) submission in 2025, relying on a streamlined single Phase 1 Human Abuse Potential study. This isn’t just a pipe dream, either. If approved, AVERSA™ Fent-a-nyl is projected to rake in U.S. sales of $80M to $200M annually—a staggering testament to its market potential. Global Intellectual Property Nutriband Inc. (NASDAQ: NTRB) isn’t just thinking local; they’re playing on a global stage. With patent approvals in China and Hong Kong, the company now boasts intellectual property coverage in 46 countries.  A U.S. Notice of Allowance for the AVERSA™ trademark further solidified their footing, giving competitors a clear signal: Nutriband Inc. (NASDAQ: NTRB) is here to lead. Strategic Fiscal Growth Numbers don’t lie. Nutriband reported record-breaking revenues in 2024, with their contract manufacturing arm, Pocono Pharma, leading the charge: A Q3 revenue of over $645k, representing a 51% year-over-year increase. Strengthened financial reserves, courtesy of $8.4M in fresh capital from a private placement. This fiscal foundation gives Nutriband Inc. (NASDAQ: NTRB) the firepower it needs to push AVERSA™ Fent-a-nyl over the finish line while continuing to innovate. Nutriband Inc. (NASDAQ: NTRB)’s 2025 Vision: Regulatory Milestones and Global Expansion Regulatory Milestones Await: The centerpiece of Nutriband Inc. (NASDAQ: NTRB)’s 2025 ambitions is the NDA submission for AVERSA™ Fent-a-nyl. With pivotal data in hand and no need for extended Phase 2 or Phase 3 trials, the company anticipates an expedited review process.  Translation? AVERSA™ Fent-a-nyl could be on the market before the year is out. Scaling for Success: Preparation for commercialization is already underway. Nutriband Inc. (NASDAQ: NTRB) is scaling its partnership with Kindeva Dr-ug Delivery to ensure manufacturing excellence.  Simultaneously, the company is laying the groundwork for international licensing and distribution agreements, proving that they aren’t content with U.S. dominance—they’re going global. A Pipeline with Potential: AVERSA™ Fent-a-nyl is just the beginning. Nutriband Inc. (NASDAQ: NTRB) is also advancing AVERSA™ Buprenorphine and exploring additional transdermal applications.  If these developments live up to their promise, Nutriband Inc. (NASDAQ: NTRB) could unlock an entirely new revenue stream, with AVERSA™ Buprenorphine alone estimated to generate $130M annually. Beyond AVERSA™: Diversification and Innovation Nutriband Inc. (NASDAQ: NTRB) isn’t putting all its eggs in one basket. The company’s manufacturing arms—Pocono Pharma and Active Intelligence—are firing on all cylinders: Expanded partnerships with retail giants like Target, Walmart, Walgreens, and CVS. Delivered innovative kinesiology and consumer health products, including an exclusive supplier agreement with Fit For Life Group, which represents Adidas, Reebok, and New Balance. Launched a Mosquito Repellent Patch in Costa Rica, marking their entry into the lucrative Central and South American markets. Why It Matters Let’s not mince words: the opioid crisis remains one of the most devastating public health challenges of our time. Nutriband Inc. (NASDAQ: NTRB) isn’t just talking about solutions; they’re delivering them. The AVERSA™ technology represents a paradigm shift in patient safety, offering a tangible way to reduce misuse, accidental exposure, and diversion of high-risk therapeutics. As CEO Gareth Sheridan aptly put it, Nutriband Inc. (NASDAQ: NTRB) is “on the brink of a transformative period in its history.”  And he’s not wrong.  The company has not only set the stage for regulatory and commercial success but also laid a solid foundation for long-term growth. The Bottom Line Nutriband Inc. (NASDAQ: NTRB) isn’t just playing in the big leagues—it’s rewriting the rulebook. With AVERSA™ Fent-a-nyl on the cusp of commercialization, an ever-expanding pipeline, and strong fiscal performance, the company is positioning itself to drive innovation and make a real-world impact in healthcare. For those watching from the sidelines, here’s your wake-up call.   Nutriband Inc. (NASDAQ: NTRB) is not just about innovation; it’s about making a meaningful impact. See Nutriband Inc. (NASDAQ: NTRB)’s corporate presentation here. Here’s 5 Reasons Why Nutriband Inc. (NASDAQ: NTRB) Is #1  on This Morning’s Watchlist 1. Limited Shares: With fewer than 5.1M shares in the float, Nutriband Inc. (NASDAQ: NTRB) has the potential for significant swings if demand starts to shift. 2. Momentum Potential: In 2024 alone, Nutriband Inc. (NASDAQ: NTRB) moved approximately 314% in under four months, highlighting its ability for significant momentum potential. 3. Innovation at the Forefront: The AVERSA™ Fent-a-nyl patch isn’t just another product—it’s a groundbreaking technology poised to redefine patient safety, with potential U.S. sales between $80M and $200M annually. 4. Under the Radar: With a market cap under $50M and record-setting revenue growth in 2024, Nutriband Inc. (NASDAQ: NTRB) appears to be flying under the radar despite its higher potential for growth. 5. Global Reach, Local Focus: A presence in 46 countries and partnerships with major retailers like Walmart and Target position Nutriband for both international growth and local execution. Don’t Overlook Nutriband Inc. (NASDAQ: NTRB)—It Belongs  on Your Radar Now Nutriband Inc. (NASDAQ: NTRB) isn’t following the crowd—it’s setting itself apart.  With a low float of fewer than 5.1M shares, this company has the potential for significant swings if demand starts to change. Combine that with its approximate 314% move in under four months last year, and the potential here is hard to ignore. At the core of Nutriband’s story is AVERSA™ Fent-a-nyl, a groundbreaking innovation poised to reshape patient safety with projected U.S. sales of $80M to $200M annually if approved.  And don’t let its market cap under $50M fool you—Nutriband is already operating on a global stage with patents in 46 countries and partnerships with major retailers like Walmart and Target. With limited shares, a proven ability to build momentum, and a vision that stretches far beyond the ordinary, Nutriband Inc. (NASDAQ: NTRB) has positioned itself as one little-known company to keep an eye on. Nutriband Inc. (NASDAQ: NTRB) has claimed the top spot on our watchlist for this morning. (NTRB) made an approximate 42% early move surpassing key moving averages while triggering 17 Bullish Signals!   Are you watching yet? Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, a multi member limited liability company. Data is provided from third-party sources and MarketCrux is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owners of Headline Media LLC own and operate marketcrux . com (“MC”). From time to time, MC will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: marketcrux.com/disclaimer/  *Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 01/21/2025 and ending on 01/22/2025 to publicly disseminate information about (NTRB:US) via digital communications. Under this agreement, Headline Media LLC has been paid seven thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from Nutriband Inc., the issuer of (NTRB:US). Neither Headline Media LLC, TD Media LLC and their members own shares of (NTRB:US). Please see important disclosure information here: https://marketcrux.com/disclosure/ntrb/

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice